Focuses on developing therapies for respiratory diseases and other pulmonary conditions.
Altamira Therapeutics Ltd., headquartered in Hamilton, Bermuda, is dedicated to developing innovative therapeutics to address a range of unmet medical needs. The company's portfolio includes Bentrio, a drug-free nasal spray designed for personal protection against airborne viruses and allergens, catering to public health concerns globally. Altamira Therapeutics is actively advancing RNA therapeutics through its OligoPhore and SemaPhore platforms, targeting extrahepatic therapeutic applications. These platforms are currently in preclinical stages, focusing on oligonucleotide and mRNA delivery.
In its clinical pipeline, Altamira Therapeutics is progressing several candidates. AM-125 is undergoing Phase II clinical trials for intranasal treatment of vertigo, aiming to address neurological disorders effectively. Keyzilen, in Phase III trials, targets acute inner ear tinnitus, addressing a significant medical challenge with potential therapeutic impact. Additionally, Sonsuvi is in Phase III development for the treathment of acute inner ear hearing loss, underscoring the company's commitment to advancing treatments for auditory health.
Founded in 2003 as Auris Medical Holding Ltd., the company rebranded as Altamira Therapeutics Ltd. in July 2021, reflecting its strategic evolution and expanded focus on therapeutic innovation. With operations spanning Switzerland, the United States, Europe, and Australia, Altamira Therapeutics remains poised to make significant strides in enhancing patient care through its diverse pipeline of cutting-edge therapies.